Thyroid Disorders
patients with systemic lupus erythematosus at particular risk? Autoimmun Rev, 2008; 8:144–6.
32. Salvi M, Vannucchi G, Campi I, et al., Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression, Eur J Endocrinol, 2006;154:511–7.
33. El Fassi D, Nielsen CH, Hasselbalch HC, Hegedus L, Treatment-resistant severe, active Graves’ ophthalmopathy successfully treated with B lymphocyte depletion, Thyroid, 2006;16:7.
34. Salvi M, Vannucchi G, Campi I, et al., Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study, Eur J Endocrinol, 2007;156:33–40.
35. Khanna D, Chong KK, Afifiyan NF, et al., Rituximab treatment of patients with severe, corticosteroid-resistant thyroid- associated ophthalmopathy, Ophthalmology, 2010;117:133–9.
36. Silkiss RZ, Reier A, Coleman M, Lauer S, Rituximab for Thyroid Eye Disease, Ophthal Plast Reconstr Surg; 2010;26:310–4.
37. Dolman PJ, Rootman J, VISA classification for Graves orbitopathy, Ophthal Plast Reconstr Surg, 2006;22:319–24.
38. Mitchell AL, Morris M, Johnson K, et al., Rituximab for refractory Graves’ orbitopathy: initial experience in Newcastle, 14Th International Thyroid Congress, Paris, September 11–16th, 2010: P0403.
39. Madaschi S, Rossini A, Formenti I, et al., Treatment of thyroid-associated orbitopathy with rituximab – a novel
therapy for an old disease: case report and literature review, Endocr Pract, 2010; 16:677–85.
40. Krassas GE, Stafilidou A, Boboridis KG, Failure of rituximab treatment in a case of severe thyroid ophthalmopathy unresponsive to steroids, Clin Endocrinol, 2010;72:853–5.
41. Salvi M, Vannucchi G, Currò N, et al., A small dose of rituximab may be sufficient to treat Graves’ orbitopathy: new insights into the mechanism of action, Arch Ophthalmol, 2011: in press.
42. El Fassi D, Nielsen CH, Bonnema SJ, et al., B lymphocyte depletion with the monoclonal antibody Rituximab in Graves’ disease. A controlled pilot study, J Clin Endocrinol Metab, 2007;92:1769–72.
43. Heemstra KA, Toes RE, Sepers J, et al., Rituximab in relapsing Graves’ disease, a phase II study, Eur J Endocrinol, 2008;159:609–15.
44. El Fassi D, Banga JP Gilbert JA, et al., Treatment of Graves’ disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies, Clin Immunol, 2009;130:252–8.
45. Huang H, Benoist C, Mathis D, Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis, Proc Nat Acad Sci, 2010;107:4658–63.
46. Smith TJ, B cell depletion in Graves’ disease: the right answer to the wrong question?, J Clin Endocrinol Metab, 2007;92:1769–72.
47. Vannucchi G, Campi I, Bonomi M, et al., Rituximab treatment in patients with active Graves’ orbitopathy: effects on proinflammatory and humoral immune reactions,
Clin Exp Immunol, 2010;161:436–43.
48. Mikozami T, Salvi M, Wall JR, Eye muscle antibodies in Graves’ ophthalmopathy: pathogenic or secondary epiphenomenon?, J Endocrinol Invest, 2004; 27:221–9.
49. Salvi M, Vannucchi G, Campi I, et al., Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates, Clin Immunol, 2009;131:360–5.
50. Tedder TF, Engel P, CD20: a regulator of cell cycle progression of B lymphocytes, Immunol Today, 1994;15:450–4.
51. Teng YK, Levarht EW, Hashemi M, et al., Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment, Arthritis Rheum, 2007;56:3909–18.
52. El Fassi D, Clemmensen O, Nielsen CH, et al., Evidence of intrathyroidal B-lymphocyte depletion after rituximab therapy in a patient with Graves’ disease, J Clin Endocrinol Metab, 2007;92:3762–3.
53. Nielsen JF, El Fassi D, Nielsen CH, et al., Evidence of orbital B and T cell depletion after rituximab therapy in Graves’ ophthalmopathy, Acta Ophthalmologica, 2009; 87:927–9.
54. Boissier MC, Assier E, Biton J, et al., Regulatory T cells (Treg) in rheumatoid arthritis, Join Bone Spine, 2009;76:10–4.
55. Xiu Y, Wong CP, Bouaziz JD, et al., B lymphocytes depletion by CD20 monoclonal antibody prevents diabetes in NOD mice despite isotype-specific differences in FcgR effector functions, J Immunol, 2008;180:2863–75.
114
EUROPEAN ENDOCRINOLOGY
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68